L

0 followers · 273 views

on the atlas — 9

highlights — 10

Pontifax Venture Capital
Inbox (1) - ellenjxu@gmail.com - Gmail
The first 3 levels of thinking (made simple) Level 1: Remember This is about memorising things. Re-reading, re-writing, rote-learning, repeating hundreds of flashcards. If you learn like this, you’re going to hate learning (unless you’re a psychopath). This level only helps with regurgitating and becomes increasingly useless as you go through uni and professional life. Confusingly, even though this level is called remember, it's actually a bad way to remember and retain what you learn... But we'll talk about that later. Level 2: Understand This is when we try to really comprehend what we're le…
Gmail
Each of these 6 levels of thinking leads to a different level of result. These levels (and the results they lead to) are: Remember → Regurgitate facts Understand → Explain concepts and processes Apply → Solve simple problems Analyse → Compare concepts and simplify information Evaluate → Strategise, prioritise and solve complex problems Create → Hypothesise new concepts and angles
Gmail
Never follow the conventional path. It's full of boredom and has the most competition.
I'm 38. If You're in Your 20's or 30's, Read This.
Raise your standards so high people think you're a psychopath
I'm 38. If You're in Your 20's or 30's, Read This.
AIDS crisis and the subsequent sanctioning of surrogate-based approvals represented a rare relaxation of regulatory standards
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blog
This laid the groundwork for the accelerated approval pathway, which was formally instituted in 1992.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blog
The idea that the pharmaceutical industry should be centrally regulated is a relatively new idea. Before the 1950s regulation was embryonic: it focused on preventing the sale of fraudulent, impure, or adulterated goods, or was limited to specific diseases or products.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blog
The biotech firm TeGenero ran into this issue during first-in-human trials in 2006, when their antibody candidate TGN1412 overstimulated trial participants’ immune systems, leading to cytokine storms that left six previously healthy volunteers hospitalised with multiple organ failure, and one patient losing fingers and toes. This happened even though there were no signs of side effects in preclinical experiments, the dose administered was 500 times lower than the safe dose in animals, and there were no obvious deficiencies in the preclinical studies or manufacturing process.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blog
The biotech firm TeGenero ran into this issue during first-in-human trials in 2006, when their antibody candidate TGN1412 overstimulated trial participants’ immune systems, leading to cytokine storms that left six previously healthy volunteers hospitalised with multiple organ failure, and one patient losing fingers and toes. This happened even though there were no signs of side effects in preclinical experiments, the dose administered was 500 times lower than the safe dose in animals, and there were no obvious deficiencies in the preclinical studies or manufacturing process.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blog